Skip to main content

Study Compares Rivaroxaban, Warfarin With Apixaban for Cirrhosis, A-Fib

Medically reviewed by Carmen Pope, BPharm. Last updated on July 9, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, July 8, 2024 -- For patients with cirrhosis and nonvalvular atrial fibrillation (AF), initiators of rivaroxaban or warfarin versus apixaban have significantly higher rates of major hemorrhage, according to a study published online July 9 in the Annals of Internal Medicine.

Tracey G. Simon, M.D., M.P.H., from Brigham and Women's Hospital in Boston, and colleagues compared the effectiveness and safety of apixaban versus rivaroxaban and versus warfarin in a population-based propensity score-matched cohort study involving patients with cirrhosis and AF.

The researchers found that compared with apixaban initiators, rivaroxaban initiators had significantly higher rates of major hemorrhagic events (rate difference, 33.1 per 1,000 person-years; hazard ratio, 1.47); no significant differences were seen in the rates of ischemic events or death. Across subgroup and sensitivity analyses, the rates of major hemorrhage were consistently higher. Compared with apixaban initiators, warfarin initiators also had significantly higher rates of major hemorrhage (rate difference, 26.1 per 1,000 person-years; hazard ratio, 1.38), especially hemorrhagic stroke (rate difference, 9.7 per 1,000 person years; hazard ratio, 2.85).

"These findings suggest apixaban may offer safety benefits over both rivaroxaban and warfarin in patients with cirrhosis and AF engaged in routine clinical care," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted July 2024

Read this next

Pulsed Field Ablation Demonstrates Favorable Safety Profile for A-Fib

THURSDAY, July 11, 2024 -- For patients with atrial fibrillation (AF), pulsed field ablation (PFA) demonstrates a favorable safety profile, according to a study published online...

Gastroesophageal Reflux Disease Increases Risk for Atrial Fibrillation

TUESDAY, July 2, 2024 -- Gastroesophageal reflux disease (GERD) is associated with an increased incidence of atrial fibrillation, according to a study published online June 2...

Rare Predicted Loss-of-Function Variants, Polygenic Risk Score Linked to Risk of A-Fib

THURSDAY, June 27, 2024 -- Rare predicted loss-of-function (pLOF) variants and a polygenic risk score (PRS) are associated with increased atrial fibrillation (AF) risk, according...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.